What is the global market size of Insilico Drug Discovery Market?

Global Insilico Drug Discovery Market size was valued at USD 2.4 billion in 2021 and is poised to grow from USD 2.8 billion in 2022 to USD 5.9 billion by 2030, growing at a CAGR of 10% in the forecast period (2023-2030).

Insilico Drug Discovery Market Size, Share, Growth Analysis, By Product(Software, Software-as-a-Service and Consultancy-as-a-Service), By Technology(Artificial Intelligence and other), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35J2032 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 60 | Figures: 75

Insilico Drug Discovery Market Dynamics

Driver

Increase in Demand for Biomarker Identification

The global in-silico drug discovery market is anticipated to have strong growth over the projected period due in large part to developments in the biomarker identification field, the focus on lowering readmission rates and medical errors, computational technical innovations in the field of computational biology, and improvements in insilico drug discovery techniques.

Restraint

Short Lifespan Creates Major Market Challenges

The In-Silico Drug Discovery market's short lifespan is its one and only restriction. Analysis periods for this technology range from tens to hundreds of nanoseconds, depending on the size of the stimulated systems and the amount of processing required. The problem with this is that the time interval—which can be anything between a few milliseconds and several seconds—is typically too brief to accurately predict protein folding. As a result, there may not be enough protein conformations sampled.

Insilico Drug Discovery Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Insilico Drug Discovery Market size was valued at USD 0 Billion in 2023 and is poised to grow from USD 0 Billion in 2024 to USD 7.26 Billion by 2032, growing at a CAGR of 10% during the forecast period (2025-2032).

The global insilico drug discovery market is highly competitive and somewhat fragmented in nature on account of the presence of multiple players. In an attempt to maintain a competitive edge, the major industry participants are implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also investing heavily on R&D activities. 'Schrödinger, Inc. ', 'OpenEye Scientific Software, Inc. ', 'Biovista Inc.', 'IBM Watson Health', 'Numerate, Inc.', 'Certara, L.P. ', 'XtalPi Inc.', 'Cloud Pharmaceuticals, Inc.', 'Atomwise, Inc.', 'Exscientia Ltd.', 'Insilico Medicine, Inc.', 'Cyclica Inc.', 'Biorelate Limited', 'Envisagenics, Inc.', 'BenevolentAI Limited', 'AI Cure Technologies Inc.', 'Genedata AG', 'BioSymetrics, Inc.', 'Recursion Pharmaceuticals, Inc.', 'Numedii, Inc.'

The global in-silico drug discovery market is anticipated to have strong growth over the projected period due in large part to developments in the biomarker identification field, the focus on lowering readmission rates and medical errors, computational technical innovations in the field of computational biology, and improvements in insilico drug discovery techniques.

The increasing adoption of cloud-based tools is driving the in-silico drug discovery market. Pharmaceutical researchers can scale up or down their computing environment as necessary thanks to cloud computing, which gives them access to practically limitless processing resources. Businesses can more easily adapt solutions to their own requirements. For instance, BT's Cloud Compute life sciences platform can provide specific pharmaceutical applications throughout the value chain, from discovery to commercial operation, ensuring that the required applications are compatible across pipelines rather than requiring all pipeline teams to use the same application.

In 2021, the in-silico drug discovery market in North America maintained the greatest proportion, at around 45%. This is explained by the critical need for drugs to treat rare disorders like Lou Gehrig's disease and cystic fibrosis. Additionally, U.S. biopharmaceutical companies are spending more money on research and development. Around $250 billion was invested in medical and R&D in the United States in 2020. The market's growth is also related to a stronger network between service providers and manufacturers in this area than in any other. Additionally, the U.S. FDA's input has helped in the creation of a flexible regulatory pathway and provided answers to a number of questions regarding the co-development process.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Insilico Drug Discovery Market Size, Share, Growth Analysis, By Product(Software, Software-as-a-Service and Consultancy-as-a-Service), By Technology(Artificial Intelligence and other), By Region - Industry Forecast 2025-2032

Insilico Drug Discovery Market Dynamics

Insilico Drug Discovery Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Insilico Drug Discovery Market?

Who are the key vendors in the Insilico Drug Discovery Market?

What is the key driver of Insilico Drug Discovery Market?

What is the key market trend for Insilico Drug Discovery Market?

Which region accounted for the largest share in Insilico Drug Discovery Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300